ASCO Annual Meeting | Conference

Novel Gastric Cancer Immunotherapy Scores Robust Phase II Results

June 6th 2016

IMAB362 reduced the risk of death or progression by approximately 50% when added to standard chemotherapy for patients with CLDN18.2-positive advanced gastric cancers.

Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC

June 6th 2016

Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

Rovalpituzumab Tesirine Shows Promising Efficacy for SCLC

June 6th 2016

Treatment with rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory small cell lung cancer.

Daratumumab Combo Shows Unprecedented PFS Benefit in Multiple Myeloma

June 5th 2016

Adding daratumumab to bortezomib and dexamethasone reduced the risk of progression or death by 61%, and doubled response rates compared with the standard 2-drug regimen alone for patients with recurrent or refractory multiple myeloma.

Adding Temozolomide to Radiotherapy Is Effective and Tolerable in Older Adults With Glioblastoma

June 5th 2016

Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.

Dr. Palumbo on CASTOR Trial Results in Multiple Myeloma

June 5th 2016

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC

June 5th 2016

Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.

Final Phase III Data Uphold CPX-351 Survival Benefit in AML

June 5th 2016

CPX-351 reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary AML.

Adding 4-1BB Agonist to Pembrolizumab Safe, Effective Across Solid Tumors

June 5th 2016

The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.

Dr. Hainsworth on Selecting Therapy Based on Genetics

June 5th 2016

John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.

Dr. Cavo on Upfront ASCT in Multiple Myeloma

June 5th 2016

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.

Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes

June 5th 2016

Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.

Nivolumab Safe, Effective in Early Stage Glioblastoma Study

June 5th 2016

Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.

Molecular Targeting Yields Responses in 12 Cancers in Off-Label Indications

June 5th 2016

Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase IIa umbrella basket study.

Large Study Gives Boost to Liquid Biopsy Testing for Mutations

June 5th 2016

The liquid biopsy testing method correlated closely with mutations described in databases and in some cases from tumor biopsies.

Patient-Driven Research Project Aims to Advance Metastatic Breast Cancer Treatment

June 5th 2016

Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.

Combining Atezolizumab With OX40 Agonist Shows Promise in Solid Tumors

June 4th 2016

A combination regimen of the PD-L1 inhibitor atezolizumab (Tecentriq) and the investigational OX40 agonist MOXR0916 was well tolerated and showed early signs of of antitumor activity in solid tumors.

Carfilzomib/Pomalidomide Regimen Warrants Further Investigation in Refractory Multiple Myeloma

June 4th 2016

A regimen consisting of carfilzomib, pomalidomide, and dexamethasone merits further investigation for the treatment of patients with multiple myeloma whose disease progresses while on lenalidomide in the earlier stages of disease.

Nivolumab/Ipilimumab Combination Active in Recurrent SCLC

June 4th 2016

Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.

Study Confirms Adjuvant Intraperitoneal Chemotherapy Is Beneficial and Well Tolerated

June 4th 2016

Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.